Authors
Latest:
Payer Perspectives on Gene Therapy ReimbursementA follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Latest:
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and PatientsUpcoming regulatory changes to create new opportunity for specialized offerings.
Latest:
Payer Perspectives on Gene Therapy ReimbursementA follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Latest:
Adapting Biopharma Launches in the COVID-19 LandscapeJudith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.
Latest:
Future-Proofing Biopharma Launches Requires Personalizing the Customer ExperienceAs the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Latest:
EMA Launches Data Standards Implementation Guide: The Time to Act is NowThe European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.
Latest:
Keeping Oncologists Current Through the Power of EducationAccording to the Centers for Disease Control and Prevention (CDC), lung cancer is the leading cause of cancer death in both men and women in the US, with about 228,150 new cases diagnosed in 2019 and approximately 143,000 deaths reported annually.
Latest:
Privacy-Safe Analytics and AI Will Accelerate Shift to Patient-Centered HealthcareHow successful commercial teams will balance the continued shift toward personalized medicine and the increased concentration on data privacy.
Latest:
Turning Detailed Drug Profiles into Targeted Business InsightsHaving invested heavily in new regulatory database systems, life sciences firms owe it to themselves to capitalize on the insights locked within those rich data assets, writes David Gwyn.
Latest:
Large Pharma Tries New Approach to Non-AdherenceMedication non-adherence is a real problem, this article looks at how to help patients better control their treatments and improve adherence.
Latest:
Digital Drives Customer-Centric Sales EngagementHow digital is helping companies increase call volumes, access to HCPs, and HCP-led dialogue.
Latest:
Preparing for Competitive Challenges to Biologics with Expiring Market ExclusivityGuidelines on how innovators can assert patents to protect their products’ exclusivity while avoiding claims from competitors and the FTC that their conduct runs afoul of U.S. antitrust law.
Latest:
Preparing for Competitive Challenges to Biologics with Expiring Market ExclusivityGuidelines on how innovators can assert patents to protect their products’ exclusivity while avoiding claims from competitors and the FTC that their conduct runs afoul of U.S. antitrust law.
Latest:
Practically Speaking: Driving Clinical TransformationThis video series discusses the impact of implementing risk-based quality management (RBQM) and decentralized clinical trials (DCTs) from the clinical operations point of view.
Latest:
The Roots and Rise of Cell and Gene TherapyContinued investment will mean new cures in a new decade.
Latest:
The Roots and Rise of Cell and Gene TherapyContinued investment will mean new cures in a new decade.
Latest:
Using Service to Drive Commercial ValueOne ‘team’ model’s advantages in brand outreach and awareness.
Latest:
Education: The Creative DifferentiatorEverything has an MOA. Bourbon has an MOA. There’s nothing unique about that. What’s differentiating is the benefit associated with the molecule’s MOA.
Latest:
Critical Connection: Patient Services and Product LaunchA look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Latest:
Critical Connection: Patient Services and Product LaunchA look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
